EPISODE · Dec 10, 2024 · 35 MIN
Episode 28 - Greg Kunst, CEO of Aurion Biotech
from The BioHub: The Top Voices in Biotech · host Max Brennan - Biotech HeadHunter
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We have the pleasure of hosting Greg Kunst, CEO of Aurion Biotech. Greg is a seasoned leader in the biotech industry with a remarkable career spanning drug development, commercialization, and market access. At Aurion, Greg has driven the company to incredible heights, raising over $200 million and securing product approval in Japan for their groundbreaking cell therapy platform. Under his leadership, Aurion has grown rapidly, with operations expanding across the U.S. and Japan. In this episode, we’ll explore Greg’s journey from his extensive experience in the industry to taking the helm at Aurion, the innovative technologies driving their mission, and what the future holds for this cutting-edge biotech company. Enjoy and stay tuned.
What this episode covers
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We have the pleasure of hosting Greg Kunst, CEO of Aurion Biotech. Greg is a seasoned leader in the biotech industry with a remarkable career spanning drug development, commercialization, and market access. At Aurion, Greg has driven the company to incredible heights, raising over $200 million and securing product approval in Japan for their groundbreaking cell therapy platform. Under his leadership, Aurion has grown rapidly, with operations expanding across the U.S. and Japan. In this episode, we’ll explore Greg’s journey from his extensive experience in the industry to taking the helm at Aurion, the innovative technologies driving their mission, and what the future holds for this cutting-edge biotech company. Enjoy and stay tuned.
NOW PLAYING
Episode 28 - Greg Kunst, CEO of Aurion Biotech
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m